Effect of 2 Anti‐Arrhythmic Drugs Aprindine and Moxaprindine on the Replication Capacity of Murine and Human Haemopoietic Cells

Publisher Website
Google Scholar
Abstract
Aprindine, a potent antiarrhythmic agent, occasionaly seems to be responsible for agranulocytosis. In order to study its potential hematological toxicity, 3 different in vitro tests were used: the capacity of human and mice bone marrow to incorporate [3H]-thymidine (3HTdR); and the capacity of stimulated human blood lymphocytes to incorporate 3HTdR; the capacity of human granulocyte-macrophage stem cells to form colonies in agar. For all these tests aprindine was toxic at concentrations close to the clincal therapeutic serum concentration. Moxaprindine, chemically very close to aprindine, also exhibit antiarrhythmic activity. It was examined in the same tests in parallel with the study of aprindine. Moxaprindine also exhibited hematological toxicity in the tests but at a significantly higher concentration, approximately twice that of aprindine. Assuming that these in vitro tests are relevant to the in vivo hematological toxicity, moxaprindine could be considered a clinically safer antiarrhythmic agent than aprindine.